Neumora Therapeutics Class Action Lawsuit
Analysis based on 6 articles · First reported Feb 06, 2025 · Last updated Feb 23, 2025
The class action lawsuit against Neumora Therapeutics, Inc. and the significant decline in its stock price (88.7% since IPO) will negatively impact investor confidence in the biotechnology sector, particularly for clinical-stage biopharmaceutical companies undergoing IPOs. It also highlights the risks associated with drug development and clinical trial outcomes for publicly traded companies.
Robbins Geller Rudman & Dowd LLP LLP announced a class action lawsuit against Neumora Therapeutics, Inc. for alleged violations of the Securities Act of 1933. The lawsuit claims that Neumora Therapeutics' IPO documents, issued on September 15, 2023, were materially false and/or misleading. Specifically, it alleges that Neumora Therapeutics amended BlackThorn Therapeutics' original Phase Two Trial inclusion criteria for Navacaprant to justify a Phase Three Program and added a prespecified analysis focusing on patients with moderate to severe major depressive disorder. Furthermore, the lawsuit states that the Phase Two Trials lacked adequate data to predict the results of the KOASTAL-1 study accurately. On January 2, 2025, Neumora Therapeutics revealed that the KOASTAL-1 study failed to meet its primary and key secondary endpoints, leading to an 88.7% decline in Neumora Therapeutics' stock price since its IPO.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard